Skip to main content

Advertisement

SpringerLink
Log in

Hepatocellular Carcinoma Risk After Hepatitis C Cure

  • Hepatitis C (J Raymould, Section Editor)
  • Published:
Current Treatment Options in Infectious Diseases Aims and scope Submit manuscript

Opinion statement

With the recent introduction of direct acting antiviral agents for hepatitis C treatment, many patients are receiving these highly effective therapies. Patients with advanced fibrosis or cirrhosis prior to antiviral treatment will have decreased but persistent risk of hepatocellular carcinoma following cure of hepatitis C. This review will discuss this risk and review current surveillance recommendations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

AFP:

Alpha-fetoprotein

AASLD:

American Association for the Study of Liver Diseases

CT:

Computed tomography

DAA:

Direct acting antiviral

GGT:

Gamma-glutamyl transferase

HCV:

Hepatitis C virus

HCC:

Hepatocellular carcinoma

HIV:

Human immunodeficiency

MRI:

Magnetic resonance imaging

SVR:

Sustained virologic response

ULN:

Upper limit of normal

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Lewis S, Roayaie S, Ward SC, Shyknevsky I, Jibara G, Taouli B. Hepatocellular carcinoma in chronic hepatitis C in the absence of advanced fibrosis or cirrhosis. Am J Roentgenol. 2013;200(6):610–6.

    Article  Google Scholar 

  2. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.

    Article  PubMed  Google Scholar 

  3. Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst. 2011;103(22):1686–95.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Saunders D, Seidel D, Allison M, Lyratzopoulos G. Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence. Aliment Pharmacol Ther. 2010;31(10):1051–63.

    PubMed  CAS  Google Scholar 

  5. ASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed 28 July 2017. The AASLD-IDSA guidelines are updated regularly and reflect the current standard for the care of patients with hepatitis C in the USA.

  6. EASL. Recommendations on treatment of hepatitis C 2016. J Hepatol. 2017 Jan;66(1):153–94.

  7. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136(1):138–48.

    Article  PubMed  CAS  Google Scholar 

  8. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148(10):728–36.

    Article  PubMed  Google Scholar 

  9. Kramer JR, Kowalkowski MA, Duan Z, Chiao EY. The effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection. J Acquir Immune Defic Syndr. 2015;68(4):456–62.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65(4):719–26.

    Article  PubMed  CAS  Google Scholar 

  11. • Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727–33.This was one of the early papers to raise concern about the risk of hepatocellular carcinoma with direct-acting antiviral agents.

    Article  PubMed  CAS  Google Scholar 

  12. • ANRS collaborative study group on hepatocellular carcinoma. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016;65(4):734–40. This was one of the early papers to raise concern about the risk of hepatocellular carcinoma with direct acting antiviral agents.

    Article  CAS  Google Scholar 

  13. Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, et al. No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol. 2016;66:S12.

    Article  Google Scholar 

  14. • Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct acting antiviral agents. Gastroenterology. 2017;153:996–1005.e1. This article disputes the suggestion that direct-acting antiviral agents are linked to hepatocellular carcinoma.

    Article  PubMed  CAS  Google Scholar 

  15. Ganne-CarriéN LR, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, et al. Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). Hepatology. 2016;64(4):1136–47.

    Article  CAS  Google Scholar 

  16. Heimbach J, Kulik LM, Finn R, Sirlin CB, Abecassis M, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2017. https://www.aasld.org/sites/default/files/guideline_documents/Heimbach_et_al-2017-Hepatology.pdf. The AASLD guideline was recently updated and provides key recommendations for management of hepatocellular carcinoma.

  17. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37–47.

    Article  PubMed  CAS  Google Scholar 

  18. Chaiteerakij R, Addissie BD, Roberts LR. Update on biomarkers of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2015;13(2):237–45.

    Article  PubMed  CAS  Google Scholar 

  19. Pocha C, Dieperink E, McMaken KA, Knott A, Thuras P, Ho SB. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography—a randomised study. Aliment Pharmacol Ther. 2013;38(3):303–12.

    Article  PubMed  CAS  Google Scholar 

  20. Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6(12):1418–24.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011;154(2):85–93.

    Article  PubMed  Google Scholar 

  22. Luo J, Yang Y, Liu J, Lu K, Tang Z, Liu P, et al. Systematic review with meta-analysis: meat consumption and the risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2014;39(9):913–22.

    Article  PubMed  CAS  Google Scholar 

  23. Zhang W, Shu XO, Li H, Yang G, Cai H, Ji BT, et al. Vitamin intake and liver cancer risk: a report from two cohort studies in China. J Natl Cancer Inst. 2012;104(15):1173–81.

    Article  PubMed  CAS  Google Scholar 

  24. Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology. 2007;132(5):1740–5.

    Article  PubMed  Google Scholar 

  25. Setiawan VW, Wilkens LR, Lu SC, Hernandez BY, Le Marchand L, Henderson BE. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology. 2015;148(1):118–25.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Department of Medicine, Gastroenterology & Hepatology Research, Duke Clinical Research Institute, Duke University School of Medicine, DUMC Box 3913, Durham, NC, 27710, USA

    Omobonike O. Oloruntoba MD & Andrew J. Muir MD

Authors
  1. Omobonike O. Oloruntoba MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew J. Muir MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew J. Muir MD.

Ethics declarations

Conflict of Interest

Dr. Oloruntoba declares that she has no conflict of interest. Dr. Muir received research grants and served on advisory boards for AbbVie, Bristol Myers Squibb, Gilead, Janssen, and Merck.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Hepatitis C

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oloruntoba, O.O., Muir, A.J. Hepatocellular Carcinoma Risk After Hepatitis C Cure. Curr Treat Options Infect Dis 10, 330–336 (2018). https://doi.org/10.1007/s40506-017-0139-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40506-017-0139-3

Keywords

Search

Navigation